Cargando…
Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
The trabecular bone score (TBS) can be determined in addition to the Dual Energy X-ray Absorptiometry (DXA) for bone mineral density (BMD) measurement to diagnose, evaluate, and stratify bone loss and decide on appropriate treatment in patients at risk. Especially in patients with secondary osteopor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299520/ https://www.ncbi.nlm.nih.gov/pubmed/37373840 http://dx.doi.org/10.3390/jcm12124147 |
_version_ | 1785064384593133568 |
---|---|
author | Al-Hashimi, Leith Klotsche, Jens Ohrndorf, Sarah Gaber, Timo Hoff, Paula |
author_facet | Al-Hashimi, Leith Klotsche, Jens Ohrndorf, Sarah Gaber, Timo Hoff, Paula |
author_sort | Al-Hashimi, Leith |
collection | PubMed |
description | The trabecular bone score (TBS) can be determined in addition to the Dual Energy X-ray Absorptiometry (DXA) for bone mineral density (BMD) measurement to diagnose, evaluate, and stratify bone loss and decide on appropriate treatment in patients at risk. Especially in patients with secondary osteoporosis, TBS detects restricted bone quality. To investigate the influence of an additional evaluation of TBS on patients’ treatment strategy decisions, we enrolled 292 patients, with a high proportion of patients with secondary osteoporosis, from one outpatient unit over one year. Patients eligible for BMD measurement had the option to opt-in for TBS measurement. We analyzed demographic data, leading diagnoses, bone metabolism parameters, and results of BMD and TBS measurements. More than 90% of patients consented to TBS measurement. TBS measurement influenced the decision in approximately 40% of patients with a treatment indication for anti-osteoporotic drugs. We demonstrate that depending on the underlying disease/risk spectrum, 21–25.5% of patients had an unremarkable BMD measurement with poor bone quality shown in the TBS measurement. In patients with secondary osteoporosis, the use of TBS supplementary to DXA seems useful to better assess fracture risk and, thus, to initiate therapy for osteoporosis in these patients in time. |
format | Online Article Text |
id | pubmed-10299520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102995202023-06-28 Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis Al-Hashimi, Leith Klotsche, Jens Ohrndorf, Sarah Gaber, Timo Hoff, Paula J Clin Med Article The trabecular bone score (TBS) can be determined in addition to the Dual Energy X-ray Absorptiometry (DXA) for bone mineral density (BMD) measurement to diagnose, evaluate, and stratify bone loss and decide on appropriate treatment in patients at risk. Especially in patients with secondary osteoporosis, TBS detects restricted bone quality. To investigate the influence of an additional evaluation of TBS on patients’ treatment strategy decisions, we enrolled 292 patients, with a high proportion of patients with secondary osteoporosis, from one outpatient unit over one year. Patients eligible for BMD measurement had the option to opt-in for TBS measurement. We analyzed demographic data, leading diagnoses, bone metabolism parameters, and results of BMD and TBS measurements. More than 90% of patients consented to TBS measurement. TBS measurement influenced the decision in approximately 40% of patients with a treatment indication for anti-osteoporotic drugs. We demonstrate that depending on the underlying disease/risk spectrum, 21–25.5% of patients had an unremarkable BMD measurement with poor bone quality shown in the TBS measurement. In patients with secondary osteoporosis, the use of TBS supplementary to DXA seems useful to better assess fracture risk and, thus, to initiate therapy for osteoporosis in these patients in time. MDPI 2023-06-20 /pmc/articles/PMC10299520/ /pubmed/37373840 http://dx.doi.org/10.3390/jcm12124147 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Al-Hashimi, Leith Klotsche, Jens Ohrndorf, Sarah Gaber, Timo Hoff, Paula Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis |
title | Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis |
title_full | Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis |
title_fullStr | Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis |
title_full_unstemmed | Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis |
title_short | Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis |
title_sort | trabecular bone score significantly influences treatment decisions in secondary osteoporosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299520/ https://www.ncbi.nlm.nih.gov/pubmed/37373840 http://dx.doi.org/10.3390/jcm12124147 |
work_keys_str_mv | AT alhashimileith trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis AT klotschejens trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis AT ohrndorfsarah trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis AT gabertimo trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis AT hoffpaula trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis |